Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Onc.AI
AddedFeb 17, 2024
UpdatedJun 18, 2026
Onc.AI

Onc.AI

Series A

Creating precision oncology software for clinical use, with a focus on physician-centered products.

HQ
San Carlos, CA, US
Founded
2020
Overview
Compare
Fundraising
Employees

Onc.AI, founded with the mission to radically improve oncology decision-making, focuses on developing AI-powered technology for precision oncology. The company offers physician-centered software designed to enhance cancer treatment decisions by leveraging a comprehensive real-world dataset that includes diagnostic imaging, EMR, labs, and genomics. Onc.AI aims to bring clarity to cancer treatment through its innovative AI models, targeting the clinical oncology market.

Notable affiliated individuals and investors include leading experts in oncology and AI, though specific names are not provided. Key achievements involve the development of their first product aimed at assisting medical professionals in making more informed treatment decisions. Onc.AI's impact lies in its potential to transform oncology by integrating advanced AI technologies with clinical data, thereby improving patient outcomes and advancing the field of precision medicine.

Onc.AI - Similar Companies

Precision Health AI logo

Precision Health AI

GenomOncology logo

GenomOncology

genomoncology.com

OncoPrecision logo

OncoPrecision

oncoprecision.bio

OncoLens logo

OncoLens

oncolens.com

Oncospace logo

Oncospace

oncospace.com

xCures logo

xCures

xcures.com

Oncora Medical logo

Oncora Medical

oncoramedical.com

Predictive Oncology logo

Predictive Oncology

VieCure logo

VieCure

viecure.com

Triomics logo

Triomics

triomics.com

Cambridge Cancer Genomics logo

Cambridge Cancer Genomics

Genomate Health logo

Genomate Health

genomate.health

Oncobox logo

Oncobox

oncobox.com

Certis Oncology Solutions logo

Certis Oncology Solutions

certisoncology.com

Fuse Oncology logo

Fuse Oncology

fuseonc.com

Onc.AI - Quick Facts

Who are Onc.AI's competitors?

Companies similar to Onc.AI include Precision Health AI, GenomOncology, OncoPrecision and OncoLens.

When was Onc.AI founded?

Onc.AI was founded in 2020.

Where is Onc.AI's headquarters located?

Onc.AI's headquarters is located in San Carlos, CA, US.

When was Onc.AI's last funding round?

Onc.AI's most recent funding round was for $25M (USD) in January 2023.

How much has Onc.AI raised to-date?

As of Jan 5, 2023, Onc.AI has raised a total of $31M (USD).

How many employees does Onc.AI have?

Onc.AI has 30 employees as of Feb 5, 2024.

Onc.AI - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Oncology Software
Tags
  • Healthtech
  • SaaS
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software